Table 1. Summary characteristics of... | Rockefeller University Press

Table 1.

Summary characteristics of patients and control subjects in this study

Patients	N	Age	Sex (male/female)	HLA-DQB106:02* positive	Prior Pandemrix immunization	Disease duration	CSF orexin levels <110 pg/ml (N/N tested)	CSF orexin levels >200 pg/ml (N/N tested)
		yr				mo
Healthy donors	25	47 (13–64)	16/9	25
Narcolepsy type 1	39	42 (13–64)	23/16	39	11	59 (8–552)	32/32
Other hypersomnias	11	25 (6–54)	3/8					10/10

Patients	N	Age	Sex (male/female)	HLA-DQB1*06:02 positive	Prior Pandemrix immunization	Disease duration	CSF orexin levels <110 pg/ml (N/N tested)	CSF orexin levels >200 pg/ml (N/N tested)
		yr				mo
Healthy donors	25	47 (13–64)	16/9	25
Narcolepsy type 1	39	42 (13–64)	23/16	39	11	59 (8–552)	32/32
Other hypersomnias	11	25 (6–54)	3/8					10/10

For age and disease duration, numbers indicate the median with the range in parentheses.